Any deviation from licensed dosing regimens should only occur under close medical supervision, as the risk-benefit profile at sub-therapeutic doses remains poorly characterised
The FDA prescribing information notes that tirzepatide is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis
As demand for weight-loss drugs rises, states grapple with Medicaid coverage In January, the National Association of Medicaid Directors told the federal Centers for Medicare & Medicaid Services that state Medicaid departments had significant concerns over the fiscal impacts of the Biden proposal to require coverage of GLP-1s, and strongly recommend that CMS maintain the current state option to cover or not cover anti-obesity medications. But others say covering the drugs will yield long-term savings
doi: 10.1038/nrdp.2016.57 159 JohamAEPiltonenTLujanMEKiconcoSTayCT
GLP1-R reduces liver fat content, improves hepatic insulin sensitivity, and decreases inflammatory cytokines
doi: 10.1097/00003081-198306000-00025
